Literature DB >> 20809202

The role of FSH and TSH in bone loss and its clinical relevance.

Manasi Agrawal1, Guangyu Zhu, Li Sun, Mone Zaidi, Jameel Iqbal.   

Abstract

Osteoporosis, a global health problem, is now frequently recognized to be secondary to alterations in the pituitary-bone axis. This review examines the current evidence for how dysregulation of the pituitary-bone axis leads to osteoporotic bone loss. Specifically, perimenopausal bone loss in the context of follicle-stimulating hormone action, and hyperthyroid bone loss in the context of thyroid-stimulating hormone action are explored. From the reviewed scientific findings, recommendations for early diagnosis and better clinical management of bone loss are made.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20809202     DOI: 10.1007/s11914-010-0028-x

Source DB:  PubMed          Journal:  Curr Osteoporos Rep        ISSN: 1544-1873            Impact factor:   5.096


  62 in total

1.  FSH directly regulates bone mass.

Authors:  Li Sun; Yuanzhen Peng; Allison C Sharrow; Jameel Iqbal; Zhiyuan Zhang; Dionysios J Papachristou; Samir Zaidi; Ling-Ling Zhu; Beatrice B Yaroslavskiy; Hang Zhou; Alberta Zallone; M Ram Sairam; T Rajendra Kumar; Wei Bo; Jonathan Braun; Luis Cardoso-Landa; Mitchell B Schaffler; Baljit S Moonga; Harry C Blair; Mone Zaidi
Journal:  Cell       Date:  2006-04-21       Impact factor: 41.582

2.  Estrogen suppresses activation but enhances formation phase of osteogenic response to mechanical stimulation in rat bone.

Authors:  C J Jagger; J W Chow; T J Chambers
Journal:  J Clin Invest       Date:  1996-11-15       Impact factor: 14.808

3.  Thyroid hormone and bone mass: the clinician's dilemma.

Authors:  D T Baran
Journal:  Thyroid       Date:  1994       Impact factor: 6.568

4.  Thyroid hormone inhibits growth and stimulates terminal differentiation of epiphyseal growth plate chondrocytes.

Authors:  Y Ishikawa; B R Genge; R E Wuthier; L N Wu
Journal:  J Bone Miner Res       Date:  1998-09       Impact factor: 6.741

5.  Thyroid-stimulating hormone restores bone volume, microarchitecture, and strength in aged ovariectomized rats.

Authors:  T Kuber Sampath; Petra Simic; Rebecca Sendak; Natasa Draca; Ann E Bowe; Stephen O'Brien; Susan C Schiavi; John M McPherson; Slobodan Vukicevic
Journal:  J Bone Miner Res       Date:  2007-06       Impact factor: 6.741

6.  Hormone predictors of bone mineral density changes during the menopausal transition.

Authors:  MaryFran R Sowers; Mary Jannausch; Daniel McConnell; Roderick Little; Gail A Greendale; Joel S Finkelstein; Robert M Neer; Janet Johnston; Bruce Ettinger
Journal:  J Clin Endocrinol Metab       Date:  2006-01-10       Impact factor: 5.958

7.  Bone remodeling increases substantially in the years after menopause and remains increased in older osteoporosis patients.

Authors:  Robert Recker; Joan Lappe; K Michael Davies; Robert Heaney
Journal:  J Bone Miner Res       Date:  2004-07-21       Impact factor: 6.741

8.  The relationship between serum TSH and bone mineral density in men and postmenopausal women: the Tromsø study.

Authors:  Guri Grimnes; Nina Emaus; Ragnar Martin Joakimsen; Yngve Figenschau; Rolf Jorde
Journal:  Thyroid       Date:  2008-11       Impact factor: 6.568

Review 9.  Hyperthyroidism, thyroid hormone therapy, and bone.

Authors:  D S Ross
Journal:  Thyroid       Date:  1994       Impact factor: 6.568

10.  High cathepsin K levels in men with differentiated thyroid cancer on suppressive L-thyroxine therapy.

Authors:  Peter Mikosch; Katharina Kerschan-Schindl; Wolfgang Woloszczuk; Haro Stettner; Stefan Kudlacek; Ewald Kresnik; Hans J Gallowitsch; Peter Lind; Peter Pietschmann
Journal:  Thyroid       Date:  2008-01       Impact factor: 6.568

View more
  8 in total

Review 1.  Biglycan in the Skeleton.

Authors:  Vardit Kram; Reut Shainer; Priyam Jani; Josephina A N Meester; Bart Loeys; Marian F Young
Journal:  J Histochem Cytochem       Date:  2020-07-06       Impact factor: 2.479

Review 2.  Bone development: overview of bone cells and signaling.

Authors:  Anna Teti
Journal:  Curr Osteoporos Rep       Date:  2011-12       Impact factor: 5.096

3.  A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study of Jianyao Migu Granules in the Treatment of Osteopenic Low Back Pain.

Authors:  Zihao Qin; Ke Xu; Wen Mo; Jie Ye; Jinhai Xu
Journal:  J Pain Res       Date:  2022-09-01       Impact factor: 2.832

Review 4.  In Vivo and In Vitro Impact of Carbohydrate Variation on Human Follicle-Stimulating Hormone Function.

Authors:  George R Bousfield; Jeffrey V May; John S Davis; James A Dias; T Rajendra Kumar
Journal:  Front Endocrinol (Lausanne)       Date:  2018-05-09       Impact factor: 5.555

5.  FSH suppression does not affect bone turnover in eugonadal men.

Authors:  Alexander V Uihlein; Joel S Finkelstein; Hang Lee; Benjamin Z Leder
Journal:  J Clin Endocrinol Metab       Date:  2014-03-19       Impact factor: 5.958

6.  A Convenient In Vivo Model Using Small Interfering RNA Silencing to Rapidly Assess Skeletal Gene Function.

Authors:  Wen Zhang; Can Liu; Bao Hai; Guohong Du; Hong Wang; Huijie Leng; Yingsheng Xu; Chunli Song
Journal:  PLoS One       Date:  2016-11-28       Impact factor: 3.240

7.  Follicle-Stimulating Hormone Increases the Risk of Postmenopausal Osteoporosis by Stimulating Osteoclast Differentiation.

Authors:  Jie Wang; Wenwen Zhang; Chunxiao Yu; Xu Zhang; Haiqing Zhang; Qingbo Guan; Jiajun Zhao; Jin Xu
Journal:  PLoS One       Date:  2015-08-04       Impact factor: 3.240

8.  Thyroid-Stimulating Hormone Within Normal Range Does Not Affect Bone Turnover in Euthyroid Postmenopausal Women with Osteoporotic Fracture - A Preliminary Report.

Authors:  Agnieszka Pater; Wieslaw Nowacki; Grazyna Sypniewska
Journal:  EJIFCC       Date:  2011-12-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.